5-HT1A Receptor
A serotonin receptor subtype that mediates anxiolytic, antidepressant, and neuroprotective effects. CBD is a partial agonist at 5-HT1A receptors.
In Depth
The 5-HT1A receptor is the primary target of buspirone (an anxiolytic) and contributes to the effects of SSRIs. CBD's agonism at 5-HT1A receptors is thought to contribute significantly to its anxiolytic and antidepressant effects. This mechanism is distinct from CBD's effects on the endocannabinoid system and may explain why CBD's anxiolytic effects are not blocked by CB1 receptor antagonists. The 5-HT1A pathway also mediates CBD's neuroprotective effects in some models.
Related Terms
Further Reading
More in Pharmacology
Endocannabinoid System (ECS)
A lipid-based retrograde neurotransmitter system comprising endogenous cannabinoids (endocannabinoids), their receptors (CB1, CB2), and metabolic enzymes.
CB1 Receptor
Cannabinoid receptor type 1. A G protein-coupled receptor (GPCR) primarily expressed in the central nervous system. The primary target of THC's psychoactive effects.
CB2 Receptor
Cannabinoid receptor type 2. A GPCR primarily expressed in immune tissues and peripheral organs. Less abundant in the CNS than CB1.
Anandamide (AEA)
N-arachidonoylethanolamine. The first endocannabinoid identified. A partial agonist at CB1 and CB2 receptors, named from the Sanskrit word "ananda" meaning bliss.
2-Arachidonoylglycerol (2-AG)
The most abundant endocannabinoid in the brain. A full agonist at both CB1 and CB2 receptors.